These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8496337)

  • 1. Generation of cellular immune responses against a glioma-associated antigen(s).
    Holladay FP; Wood GW
    J Neuroimmunol; 1993 Apr; 44(1):27-32. PubMed ID: 8496337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
    Holladay FP; Lopez G; De M; Morantz RA; Wood GW
    Neurosurgery; 1992 Apr; 30(4):499-504; discussion 504-5. PubMed ID: 1584347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes.
    Holladay FP; Heitz T; Chen YL; Chiga M; Wood GW
    Neurosurgery; 1992 Sep; 31(3):528-33. PubMed ID: 1407433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of cytotoxic immune responses during the progression of a rat glioma.
    Holladay FP; Choudhuri R; Heitz T; Wood GW
    J Neurosurg; 1994 Jan; 80(1):90-6. PubMed ID: 8271027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune rejection of intracerebral gliomas using lymphocytes from glioma-bearing rats.
    Wood GW; Turner T; Wang YY; Holladay FP
    J Immunother; 1999 Nov; 22(6):497-505. PubMed ID: 10570748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas.
    Sanchez R; Williams C; Daza JL; Dan Q; Xu Q; Chen Y; Delgado C; Arpajirakul N; Jeffes EW; Kim RC; Douglass T; Al Atar U; Terry Wepsic H; Jadus MR
    Cell Immunol; 2002 Jan; 215(1):1-11. PubMed ID: 12142031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
    Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
    Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
    Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
    Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
    Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
    Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.
    Baldwin NG; Rice CD; Tuttle TM; Bear HD; Hirsch JI; Merchant RE
    J Neurooncol; 1997 Mar; 32(1):19-28. PubMed ID: 9049859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated immune response in rats immunized with chemically modified syngeneic glioma cells. Monitoring by in vivo parameters and in vitro immune cytolysis.
    Bilzer T; Stavrou D; Dahme E; Anzil AP
    Anticancer Res; 1982; 2(6):345-54. PubMed ID: 6984814
    [No Abstract]   [Full Text] [Related]  

  • 14. The humoral antibody response of rats immunized with chemically modified syngeneic brain cells and glioma cells.
    Stavrou D; Hultén M; Anzil AP; Bilzer T
    Int J Cancer; 1980 Nov; 26(5):629-37. PubMed ID: 7239719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
    Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
    Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
    Jachimczak P; Bogdahn U; Schneider J; Behl C; Meixensberger J; Apfel R; Dörries R; Schlingensiepen KH; Brysch W
    J Neurosurg; 1993 Jun; 78(6):944-51. PubMed ID: 8487077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ T-cell mediated anti-tumor responses cross-reacting against 9L and RT2 rat glioma cell lines.
    Shah MR; Ramsey WJ
    Cell Immunol; 2003 Oct; 225(2):113-21. PubMed ID: 14698145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas.
    Gately MK; Glaser M; Dick SJ; Mettetal RW; Kornblith PL
    J Natl Cancer Inst; 1982 Dec; 69(6):1245-54. PubMed ID: 6183477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination.
    Graf MR; Prins RM; Hawkins WT; Merchant RE
    Cancer Immunol Immunother; 2002 Jun; 51(4):179-89. PubMed ID: 12012105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of interleukin-2 in immune surveillance against brain tumors.
    Yoshida S; Takai N; Tanaka R
    Neurosurgery; 1987 Nov; 21(5):627-30. PubMed ID: 3501073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.